Circulating Tumor Cell Device Gets Safer FDA Classification
Published Date: 5/6/2026
Rule
Summary
The FDA is officially classifying the circulating tumor cell enrichment device as a Class II device, meaning it has special safety rules but fewer hurdles than the strictest category. This change helps patients get access to innovative cancer-fighting tools faster and keeps the device safe and effective. The new rules take effect May 6, 2026, and could save time and money for makers and users of this device.
Free Policy Watch
New rules are filed every week. Most people never see them.
Pick a topic. PRIA watches every federal rule and tells you when one hits your household.
Pick a topic to get started
Analyzed Economic Effects
4 provisions identified: 3 benefits, 1 costs, 0 mixed.
Easier Path for Future Devices
FDA states that once this device type is classified into Class II via the De Novo process, it can serve as a predicate for future devices. That means other device sponsors may be able to use the less-burdensome 510(k) process to bring substantially equivalent devices to market instead of submitting a De Novo request or a premarket approval application.
Device Reclassified to Class II
FDA has classified the circulating tumor cell enrichment device as Class II (special controls). This order is effective May 6, 2026 (and the classification was applicable May 24, 2022). FDA says this classification will provide reasonable assurance of safety and effectiveness and will enhance patients' access to innovative devices by reducing regulatory burdens.
Manufacturers Must Meet Special Controls
Circulating tumor cell enrichment devices remain subject to premarket notification under section 510(k) and must meet the special controls codified at 21 CFR 866.6110. Manufacturers must provide specified labeling (including intended use, limitations, and troubleshooting) and design verification and validation data, including analytical and clinical study documentation demonstrating performance, detection limits, precision, recovery, and stability.
Labeling Limits Use; Not Diagnostic
The device's labeling must prominently state that the standalone device is intended only to enrich circulating tumor cells (CTCs) from peripheral blood of previously diagnosed cancer patients and is not intended for diagnostic, prognostic, or monitoring use. Labeling must also state that results do not provide information about a patient's current health and that downstream assays need separate validation.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Take It Personal
Get Your Personalized Policy View
Take the PRIA Score to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in